tiprankstipranks
Trending News
More News >
OKYO Pharma Limited Sponsored ADR (OKYO)
NASDAQ:OKYO
US Market

OKYO Pharma Limited Sponsored ADR (OKYO) AI Stock Analysis

Compare
72 Followers

Top Page

OK

OKYO Pharma Limited Sponsored ADR

(NASDAQ:OKYO)

38Underperform
OKYO Pharma Limited's stock is primarily affected by its significant financial challenges, including no revenue generation and negative equity. Technical analysis provides a neutral to slightly bearish outlook, while traditional valuation metrics are not applicable, reflecting typical biotech industry characteristics.
Positive Factors
Clinical Development
OKYO Pharma announced its plan to accelerate the clinical development of urcosimod for the treatment of neuropathic corneal pain with early closure of the Phase 2 trial.
Patient Interest
A number of patients from the trial have requested continued compassionate use of urcosimod, subject to necessary FDA consents, and a considerable number of potential patients have expressed an interest in participating in a future registrational trial.
Negative Factors
Financial Risk
The company needs to raise additional capital within the next 12 months to fund operations.
Regulatory Approval Risk
Risks include failure of OK-101 in clinical trials, failure to secure regulatory approval in the U.S., failure to achieve commercial success, and dilution risk.

OKYO Pharma Limited Sponsored ADR (OKYO) vs. S&P 500 (SPY)

OKYO Pharma Limited Sponsored ADR Business Overview & Revenue Model

Company DescriptionOKYO Pharma Limited Sponsored ADR (OKYO) is a biotechnology company specializing in the development of innovative therapies for inflammatory eye diseases and chronic pain. The company operates within the pharmaceutical and healthcare sector, focusing on leveraging scientific research to address unmet medical needs. OKYO's core products include proprietary drug candidates aimed at treating conditions such as dry eye disease and ocular pain.
How the Company Makes MoneyOKYO Pharma Limited generates revenue primarily through the development and potential commercialization of its drug candidates. The company makes money by advancing its therapeutic products through clinical trials and ultimately obtaining regulatory approvals to market them. Revenue streams may include licensing agreements with larger pharmaceutical companies, milestone payments, and royalties from any successful commercialization of its treatments. Additionally, OKYO may engage in strategic partnerships or collaborations that provide funding and resources to support its research and development efforts.

OKYO Pharma Limited Sponsored ADR Financial Statement Overview

Summary
OKYO Pharma Limited faces significant financial challenges, with no revenue generation, negative equity, and persistent cash outflows. These factors highlight substantial financial risk, especially given ongoing R&D investments without profitability improvements.
Income Statement
10
Very Negative
OKYO Pharma Limited has shown no total revenue over the past years, reflecting the challenges in generating sales typical in the biotechnology industry. Net income remains negative, indicating ongoing operational and developmental expenses without offsetting revenue.
Balance Sheet
20
Very Negative
The balance sheet indicates a concerning negative stockholders' equity, which is a risk factor for financial stability. The total liabilities exceed total assets, which may affect the company's ability to raise capital. The debt-to-equity ratio cannot be calculated due to negative equity, further highlighting financial risk.
Cash Flow
15
Very Negative
OKYO's cash flow is characterized by negative operating cash flow and free cash flow, suggesting significant cash burn typical for R&D-focused biotech firms. However, the company has managed to secure financing inflows, which partially mitigates cash flow concerns.
Breakdown
Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Income StatementTotal Revenue
0.000.000.000.000.00
Gross Profit
-13.09K
EBIT
-13.19M-6.22M-1.52M
EBITDA
-13.18M-6.22M-3.35M-1.51M
Net Income Common Stockholders
-13.27M-5.43M-3.35M-1.54M
Balance SheetCash, Cash Equivalents and Short-Term Investments
826.85K4.05M2.70M6.89M234.96K
Total Assets
1.54M5.20M4.30M7.09M597.40K
Total Debt
0.002.22M0.0098.76K31.62K
Net Debt
-826.85K-1.83M-2.70M-6.79M-203.34K
Total Liabilities
7.42M7.26M1.35M1.77M737.20K
Stockholders Equity
-5.88M-2.05M2.95M5.32M
Cash FlowFree Cash Flow
-9.49M-7.70M-5.47M-1.61M-1.20M
Operating Cash Flow
-9.49M-7.70M-5.47M-1.60M-1.20M
Investing Cash Flow
0.00-5.92K-1.67K-18.11K-132.67K
Financing Cash Flow
6.21M9.32M2.15M7.83M963.31K

OKYO Pharma Limited Sponsored ADR Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.58
Price Trends
50DMA
1.27
Positive
100DMA
1.17
Positive
200DMA
1.15
Positive
Market Momentum
MACD
0.06
Negative
RSI
68.08
Neutral
STOCH
70.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OKYO, the sentiment is Positive. The current price of 1.58 is above the 20-day moving average (MA) of 1.23, above the 50-day MA of 1.27, and above the 200-day MA of 1.15, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 68.08 is Neutral, neither overbought nor oversold. The STOCH value of 70.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OKYO.

OKYO Pharma Limited Sponsored ADR Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
58
Neutral
$52.91M-158.63%57.09%52.18%
BNBNR
52
Neutral
$31.42M-51.22%-10.56%41.02%
52
Neutral
$5.38B3.59-41.63%2.87%17.72%1.87%
51
Neutral
$58.24M-46.63%4.58%10.59%
42
Neutral
$40.45M-76.33%-90.55%-55.06%
38
Underperform
$53.71M0.00%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
OKYO
OKYO Pharma Limited Sponsored ADR
1.58
0.04
2.60%
ECOR
Electrocore
7.36
1.24
20.26%
BNR
Burning Rock Biotech
2.92
-4.67
-61.53%
RPTX
Repare Therapeutics
1.41
-1.94
-57.91%
HOWL
Werewolf Therapeutics
0.90
-5.18
-85.20%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.